These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31588558)

  • 1. Ethoxy mansonone G as an anticancer agent in estrogen receptor-positive and endocrine-resistant breast cancer.
    Chonsut P; Mahalapbutr P; Pradubyat N; Chavasiri W; Wonganan P; Ketchart W
    J Pharm Pharmacol; 2019 Dec; 71(12):1839-1853. PubMed ID: 31588558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of ethoxy mansonone G: A comprehensive exploration of its anticancer actions in breast cancer, colorectal cancer, and non-small cell lung carcinoma.
    Fayyaz A; Basit M; Farooq A; Khan T; Ayub U; Khan S; Armaghan M; Mati-Ur-Rahman ; Ammad M; Büsselberg D; Khan K; Habtemariam S; Sharifi-Rad J
    Cell Biol Int; 2024 Sep; 48(9):1229-1239. PubMed ID: 38924324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
    Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
    Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
    Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
    Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
    Xiong H; Jin X; You C
    Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
    Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
    Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK; Abrahamsson A; Dabrosin C
    Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
    Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
    Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.
    Cheng R; Liu YJ; Cui JW; Yang M; Liu XL; Li P; Wang Z; Zhu LZ; Lu SY; Zou L; Wu XQ; Li YX; Zhou Y; Fang ZY; Wei W
    Oncotarget; 2017 May; 8(18):30252-30264. PubMed ID: 28415819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Napabucasin Attenuates Resistance of Breast Cancer Cells to Tamoxifen by Reducing Stem Cell-Like Properties.
    Liu X; Huang J; Xie Y; Zhou Y; Wang R; Lou J
    Med Sci Monit; 2019 Nov; 25():8905-8912. PubMed ID: 31760402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF-7/SC Breast Cancer Cells.
    To NB; Truong VN; Ediriweera MK; Cho SK
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin Treatment Promotes Re-expression of Estrogen Receptor in Endocrine Therapy-resistant Hormone Receptor-positive Breast Cancer Cells.
    Goto W; Kashiwagi S; Iimori N; Kouhashi R; Yabumoto A; Takada K; Asano Y; Tauchi Y; Ogisawa K; Morisaki T; Shibutani M; Tanaka H; Maeda K
    Anticancer Res; 2023 Feb; 43(2):603-611. PubMed ID: 36697070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
    Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
    Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
    Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
    Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
    Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
    Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
    Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
    Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.